Longeveron Shares Gain After Lead Product Gets FDA Orphan Drug Tag

 The FDA has granted Orphan Drug designation to Longeveron Inc's 

LGVN +0%

 (Get Free Alerts for LGVN) lead investigational product Lomecel-B for Hypoplastic left heart syndrome (HLHS).

• Lomecel-B is a cell-based therapy product derived from culture-expanded medicinal signaling cells (MSCs), sourced from the bone marrow of young, healthy adult donors. 
• See here Benzinga's Full FDA Calendar.
• HLHS is a congenital disability that affects normal blood flow through the heart. As the baby develops during pregnancy, the left side of the heart does not form correctly. 
• Hypoplastic left heart syndrome is one type of congenital heart defect.
• Last month, The FDA granted Rare Pediatric Disease (RPD) designation Lomecel-B for Hypoplastic Left Heart Syndrome.

https://www.benzinga.com/general/biotech/21/12/24426342/longeveron-shares-gain-after-lead-product-gets-fda-orphan-drug-tag-for-type-of-congenital-heart-d